Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice  by Bengtsson, Karin Lövgren et al.
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a  b  s  t  r  a  c  t
Ebola  virus  (EBOV)  causes  severe  hemorrhagic  fever  for which  there  is no  approved  treatment  or  pre-
ventive  vaccine.  Immunological  correlates  of  protective  immunity  against  EBOV  disease  are  not  well
understood.  However,  non-human  primate  studies  have  associated  protection  of  experimental  vaccines
with binding  and  neutralizing  antibodies  to the  EBOV  glycoprotein  (GP)  as  well  as  EBOV  GP-speciﬁc  CD4+
and  CD8+ T cells.  In this  report  a full  length,  unmodiﬁed  Zaire  EBOV  GP  gene  from  the  2014  EBOV  Makona
strain  (EBOV/Mak)  was  cloned  into  a baculovirus  vector.  Recombinant  EBOV/Mak  GP  was  produced  in
Sf9 insect  cells  as  glycosylated  trimers  and, when  puriﬁed,  formed  spherical  30–40  nm  particles.  In mice,
EBOV/Mak  GP  co-administered  with  the saponin  adjuvant  Matrix-M  was  signiﬁcantly  more  immuno-
genic,  as  measured  by  virus  neutralization  titers  and  anti-EBOV/Mak  GP  IgG as  compared  to immunization
with  AlPO4 adjuvanted  or  non-adjuvanted  EBOV/Mak  GP.  Similarly,  antigen  speciﬁc  T  cells  secreting
IFN-  were  induced  most  prominently  by  EBOV/Mak  GP with  Matrix-M.  Matrix-M  also enhanced  the
frequency  of antigen-speciﬁc  germinal  center  B cells  and follicular  helper  T (TFH)  cells  in  the  spleen  in
a  dose-dependent  manner.  Immunization  with  EBOV/Mak  GP  with  Matrix-M  was  100% protective  in a
lethal viral  challenge  murine  model;  whereas  no  protection  was  observed  with  the  AlPO4 adjuvant  and
only  10%  (1/10)  mice  were  protected  in the  EBOV/Mak  GP  antigen  alone  group.  Matrix-M  adjuvanted
vaccine  induced  a rapid  onset  of  speciﬁc  IgG and  neutralizing  antibodies,  increased  frequency  of  mul-
tifunctional  CD4+  and  CD8+ T cells,  speciﬁc  TFH cells,  germinal  center  B  cells,  and  persistence  of EBOV
GP-speciﬁc  plasma  B cells  in  the  bone  marrow.  Taken  together,  the addition  of  Matrix-M  adjuvant  to  the
EBOV/Mak  GP nanoparticles  enhanced  both  B and  T-cell  immune  stimulation  which  may  be  critical  for
an Ebola  subunit  vaccine  with  broad  and  long  lasting  protective  immunity.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. IntroductionThe extent of the recent Ebola outbreak in Western Africa has
rought world-wide attention to the lack of therapeutic and pre-
entive measures against EBOV disease (EVD) and has spurred
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intense actions towards development of vaccine candidates, and
a broad range of technologies and approaches are being explored
[1,2].
Matrix-MTM, an adjuvant based on saponin extracted from the
Quillaja saponaria Molina tree induces high and long-lasting levels
of broadly reacting antibodies supported by a balanced TH1 and
TH2 type of response, including biologically active antibody iso-
types such as murine IgG2a, multifunctional T cells and cytotoxic
T lymphocytes [3–10]. The mode-of-action of Matrix-M adjuvant
has not been elucidated in detail; however, the adjuvant promotes
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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apid and profound effects on cellular drainage to local lymph nodes
reating a milieu of activated cells including T cells, B cells, Natural
iller cells, neutrophils, monocytes and dendritic cells [10–12].
Matrix-M has shown potent adjuvant activities, inducing
nhanced immune responses in preclinical [3,4,6,7,13] and human
linical studies [5], most recently with H7N9 avian inﬂuenza
irus like particle vaccine where Matrix-M adjuvanted vaccine
ad a signiﬁcant dose-sparing effect and an acceptable safety
roﬁle [14].
Immune correlates of durable protection to EVD are to date
ot clearly identiﬁed. Preclinical immunization studies in rodents
nd non-human primates (NHP), as well as protective efﬁcacy
emonstrated with reconvalescent plasma [15] and monoclonal
ntibody cocktails in vitro, in rodents [16], in NHP [17–19] and
n man  [20], point towards antibodies being a crucial protective
lement.
The potential importance of a cellular response supporting the
evelopment of a protective humoral response was demonstrated
y Marzi and co-workers [21] in a NHP challenge study with a
ive vector based rVSV/ZEBOV-GP vaccine. T cell depletion stud-
es showed CD4+ T cells to be crucial during the generation of
he antibody response but not at challenge, implicating a strong
upportive role of CD4+ cells in the development of a protective
ntibody response.
The role of prophylactic effector T cell responses to protect
gainst EVD is unclear; however, published data show a possible
upportive role in the generation of protection in NHP challenge
tudies [22]. Particularly, IFN- producing CD4+ cells are responsi-
le for a whole range of effector functions and polarization of both
umoral and cellular responses [23,24]. In addition, studies eval-
ating chimpanzee adenovirus EBOV GP vectors suggest a role of
D8+ T cell mediated responses in protection [22].
To date, the majority of EBOV vaccine approaches with posi-
ive NHP protection data involve the use of viral vectors or viral
himaeras [2]. Inactivated virus and sub-unit approaches have
ad limited success, particularly in non-human primates [2,25].
owever, there are some positive studies using potent TH1 type
timulatory adjuvants [26,27].
In the present study, we used EBOV/Mak GP nanoparticles
roduced in Sf9 cells infected with recombinant baculovirus
xpressing EBOV/Mak GP [28] combined with Matrix-M [12]. Mice
ere immunized with EBOV/Mak GP alone or adjuvanted with
atrix-M or AlPO4. The EBOV/Mak GP speciﬁc IgG, IgG1 and IgG2a
esponse, as well as the virus neutralizing antibody response and
rotection against viral challenge were evaluated.
In a separate series of experiments, the nature of the T cell
esponses were analysed by cytokine proﬁling and intracellular
taining. In addition, GC reaction and TFH cell frequencies were
easured, and the longevity of T and B cell responses studied at
ay 60 after immunization.
. Materials and methods
.1. EBOV glycoprotein nanoparticles
The wild-type full-length, unmodiﬁed Zaire EBOV glycoprotein
GP) gene from the 2014 Makona EBOV was cloned into recombi-
ant baculovirus and expressed in Spodoptera frugiperda Sf9 insect
ells as described by Hahn et al. [28]. Puriﬁed EBOV Makona
P (EBOV/Mak GP) nanoparticles are composed of multiple GP
rimers assembled into spherical particles 36 ± 4 nm (as measured
y dynamic light scattering). Recombinant GP nanoparticles have
 core region which contains the glycoprotein 2 (GP2) ‘fusion sub-
nits’ with 2–9 or more “chalice-like” glycoprotein 1 (GP1) trimers
attachment subunits’ extending outward. 34 (2016) 1927–1935
2.2. Matrix-M adjuvant
Novavax proprietary adjuvant Matrix-MTM is a saponin-based
adjuvant consisting of two  populations of individually formed
40 nm sized Matrix particles, each with a different and well-
characterized saponin fraction with complementary properties
(Fraction-A and Fraction-C, respectively). Matrix-M, used in this
study, consists of 85% Matrix-A and 15% Matrix-C. The Matrix par-
ticles are formed by formulating puriﬁed saponin from Q. saponaria
Molina with cholesterol and phospholipid [29].
2.3. Animals and ethics statement
All animal research was conducted in accordance with the NRC
Guide for the Care and Use of Laboratory Animals, the Animal
Welfare Act and the CDC/NIH Biosafety in Microbiological and
Biomedical Laboratories.
Following EBOV challenge, mice were monitored two  or more
times daily and their status evaluated by direct observation. Ani-
mal  were assigned a disease score based on assessments given for
weight loss, dyspnea, responsiveness, abnormal hair coat, eye and
nasal abnormalities including discharge (Supplemental Tables 1
and 2). Mice that achieved a disease score of 12 were considered
moribund, indicating that euthanasia criteria were met  and mice
were euthanized for humane purposes by CO2 inhalation followed
by conﬁrmatory cervical dislocation.
2.4. Vaccination and challenge
BALB/c mice (6–8 weeks old; Harlan Laboratories Inc., Frederick,
MD)  were immunized by SC injection at Days 0, 14 and 28 with 5 g
EBOV/Mak GP antigen alone or adjuvanted with AlPO4 (50 g) or
Matrix-M (5 g) in a dose volume of 100 l. Blood for serum was
collected via the retro-orbital route on Days 0, 21 and 28. Prior
to blood collection, animals were anesthetized with isoﬂurane. On
Study Day 32, the mice were transferred to the BSL-4 facility (Texas
Biomedical Research Institute, San Antonio, TX) and on Study Day
42 (14 days following the third immunization), mice were chal-
lenged by an intraperitoneal inoculation of 1000 pfu mouse adapted
Zaire EBOV strain 1976 Mayinga [30].
2.5. Vaccination and characterization of responses
BALB/c mice (n = 5 per group) were immunized by IM adminis-
tration (50 l injection volume) at Days 0 and 21 with EBOV/Mak
GP alone or mixed with AlPO4 (50 g) or Matrix-M adjuvant (2.5 or
5 g). Blood samples were collected via the retro-orbital route at
Days 0, 14, 21, 28 and 60. Spleen and bone marrow samples were
collected at Days 28 and 60. Spleen and bone marrow samples were
suspended in PBS containing 2% fetal bovine serum (FBS) for further
preparation.
2.6. Virus neutralizing activity
Serum samples from day 28 were evaluated for anti-EBOV/Mak
neutralizing antibody responses at U.S. Army Medical Research
Institute of Infectious Diseases, Fredrick, MD  using a pseudovirion
neutralization assay [31]. For this assay, the vesicular stomatitis
virus G protein was removed and replaced with luciferase reporter.
This VSV luciferase expressing core was pseudotyped using the
plasmid pWRG/EBOV-Z76(opt) that expresses the Zaire EBOV 1976
(Mayinga) GP. PsVs were prepared in 293 T cells. The assay posi-
tive control was serum from a rabbit vaccinated three times with
the pWRG/EBOV-Z76(opt), a Zaire EBOV 1976 Mayinga GP  DNA
vaccine.
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.7. Anti-EBOV/Mak GP ELISA
EBOV/Mak GP speciﬁc serum antibodies were quantitated by
nzyme linked immunosorbent assay (ELISA) as described previ-
usly [32]. NUNC MaxiSorp microtiter plates were coated with
 g/ml of EBOV/Mak GP (Novavax) overnight at 2–8 ◦C. Mouse
nti-EBOV/Mak GP monoclonal antibody 4F3 from IBT Bioservices
Gaithersburg, MD)  was used as the positive control.
.8. IFN- ELISPOT assay
Spleen cells were washed twice with PBS containing 2% FBS and
ounted. IFN- ELISPOT assays were performed using mouse IFN-
LISPOT kits (eBioscience, San Diego, CA) according to the manu-
acturer’s procedure. Brieﬂy, anti-IFN- antibody (15 g/ml in PBS)
as used to coat ELISPOT plates (Millipore, Darmstadt, Germany)
nd incubated, overnight at 4 ◦C. The plates were washed with
BS and blocked with RPMI1640 medium plus 5% FBS for 1–2 h
t room temperature. A total of 3 × 105 splenocytes in a volume
f 200 l were stimulated with pools of 15-mer EBOV GP peptides
ith 11 overlapping amino acids (2.5 g/ml) covering the entire
BOV GP sequence. Phorbol myristic acetate (PMA) (50 ng/ml) plus
onomycin (200 ng/ml) was used as positive control and medium
s negative control. Each stimulation condition was  carried out in
riplicate. Assay plates were incubated overnight at 37 ◦C in a 5%
O2 incubator and developed using BD ELISPOT AEC substrate set
BD Biosciences, San Diego, CA). Spots were counted and analyzed
sing an ELISPOT reader and Immunospot software (Cellular Tech-
ology, Ltd., Shaker Heights, OH). The number of IFN-secreting
ells induced by EBOV GP peptides was obtained by subtracting the
ackground number in the medium controls from the GP-peptide
timulated wells. Data shown in the graph are the average of trip-
icate wells.
.9. Anti-EBOV/Mak GP IgG secreting cell ELISPOT
To measure GP-speciﬁc IgG-secreting cells, ELISPOT plates were
oated with EBOV/Mak GP (2.5 g/ml) and incubated overnight at
◦C. Plates were washed and blocked as described above. Tripli-
ates of 3-5 × 105 splenocytes or bone marrow cells per well were
lated and incubated overnight at 37 ◦C. Plates were washed and
oat anti-mouse IgG-HRP was added and incubated for 1.5 h. Spots
ere developed and counted as described above. The average spot
umber from triplicate wells were calculated and presented.
.10. Surface staining for cell phenotypes and intracellular
taining for cytokines
For surface staining, cells were ﬁrst incubated with anti-
D16/32 antibody to block the Fc receptor. To characterize the
erminal center cells, 1 × 106 splenocytes were incubated at 4 ◦C
or 30 min  with a mixture of the following antibodies: B220-
erCP, CD19-APC, GL7-BV421, CD95-PE-Cy7 (BD Biosciences) and
he yellow LIVE/DEAD® dye (Life Technologies, NY). To stain T
ollicular helper cells, 1 × 106 splenocytes were incubated with
XCR5-Biotin, washed, then incubated with a mixture of antibodies
ncluding CD3-BV650, B220-PerCP, CD4-PE-Cy7, Streptavidin-
V421, PD-1-APC, CD69-FITC and CD49b-PE (BD Biosciences) and
he yellow LIVE/DEAD® dye. Cells were washed and suspended in
BS containing 2% FBS for analysis.
For intracellular staining for cytokines, splenocytes were cul-
ured in a 96-well U-bottom plate at 1 × 106 cells per well. The
eptide stimulation was performed as described for the ELISPOT
ultures. The plate was incubated 6 h at 37 ◦C in the presence
f BD GolgiPlugTM and BD GolgiStopTM (BD Biosciences). Cells
ere washed and incubated for 20 min  at 4 ◦C with a mixture of 34 (2016) 1927–1935 1929
antibodies including CD3-BV650, CD4-PerCP, CD8-FITC, CD44-APC-
Cy7 and CD62L-PE-Cy7 (BD Pharmingen, CA) and the yellow
LIVE/DEAD® dye (Life Technologies, NY). After two washes, cells
were ﬁxed with Cytoﬁx/Cytoperm (BD Biosciences) for 30 min at
4 ◦C, followed by two  washes with BD Perm/WashTM (BD Bio-
sciences). Cells were incubated with antibodies to IFN--APC,
IL-2-BV 421 and TNF-PE (BD Biosciences) overnight at 4 ◦C. The
cells were washed and re-suspended in 1xBD Perm/Wash buffer for
data acquisition. All staining samples were acquired using a LSR-
Fortessa ﬂow cytometer (Becton Dickinson, San Jose, CA) and the
data were analysed with Flowjo software version Xv10 (Tree Star
Inc., Ashland, OR).
2.11. Statistical analysis
Statistical analysis was  performed using SAS software version
9.4. Pairwise comparisons with Tukey’s adjustment from ANOVA
used group as the independent variable and log-transformed titer
result as the dependent variable to determine signiﬁcance between
groups. Statistical analysis of Kaplan-Meier survival curves was
done by Log-Rank analysis.
3. Results
3.1. Immunogenicity and protective efﬁcacy of EBOV/Mak GP
vaccine
The immunogenicity of the EBOV/Mak GP nanoparticle vac-
cine was  evaluated with and without adjuvant in a mouse model.
Mice were vaccinated on Days 0, 14 and 28 by SC injection with
5 g of EBOV/Mak GP alone or formulated in Matrix-M or AlPO4
adjuvant. Analysis of sera obtained on Day 28 indicated that the
Matrix-M adjuvanted EBOV/Mak GP induced high levels of antigen-
speciﬁc IgG antibodies (Fig. 1A). The response obtained following
immunization with EBOV/Mak GP with Matrix-M was signiﬁcantly
higher than those induced by EBOV/Mak GP alone (p < 0.0001) or
EBOV/Mak GP adjuvanted with AlPO4 (p < 0.0001).
Low levels of neutralization activity were observed in sera from
mice immunized with the EBOV/Mak GP alone and EBOV/Mak GP
adjuvanted with AlPO4 (Fig. 1B). Neutralization titers observed in
sera from mice immunized with EBOV/Mak GP with Matrix-M were
thirty-two-fold higher than that obtained with EBOV/Mak GP alone
(p < 0.0001). As PsVs expressing the EBOV 1976 Mayinga strain GP
were used, assay is measuring the cross-neutralizing activity of
anti-EBOV/Mak GP against the Mayinga GP.
On Day 42, mice were challenged by an intraperitoneal inocu-
lation of 1000 pfu mouse adapted Zaire EBOV strain 1976 Mayinga.
Control mice started to succumb to infection after three days while
mice vaccinated with EBOV/Mak GP alone or EBOB/Mak GP adju-
vanted with AlPO4 succumbed at day ﬁve or six, respectively.
Twenty-one days after challenge infection, all mice vaccinated with
Matrix-M adjuvanted EBOV/Mak GP and one mouse vaccinated
with EBOV/Mak GP alone were alive and healthy (Fig. 1C).
3.2. CD4+, CD8+, and multifunctional T cell response
To assess T cell responses, the number of IFN- secreting T
cells after ex vivo stimulation of spleen cells with EBOV/Mak GP
peptides in an ELISPOT assay were determined. At Day 28, IFN-
secreting cells increased in a Matrix-M dose-dependent manner
in spleens from mice immunized with EBOV/Mak GP with Matrix-
M (Fig. 2A and B). The average number of IFN--secreting cells in
groups receiving EBOV/Mak GP with 5.0 and 2.5 g of Matrix-M
were 17- and 10-fold higher, respectively, than in the group receiv-
ing EBOV/Mak GP alone and 8- and 5-fold higher, respectively, than
in the group receiving EBOV/Mak GP with AlPO4 (Fig. 2A).
1930 K.L. Bengtsson et al. / Vaccine 34 (2016) 1927–1935
Fig. 1. EBOV/Mak GP induced antibody response and protective efﬁcacy. Mice were immunized SC on Days 0, 14 and 28 with 5 g EBOV/Mak GP, 5 g EBOV GP adjuvanted
with  50 g AlPO4 or 5 g EBOV/Mak GP adjuvanted with 5 g Matrix-M. Serum was obtained on Day 28 and evaluated by ELISA for anti-EBOV/Mak GP IgG (A) or anti-Ebola
virus  neutralizing antibody (B). Black bars represent the group GMT and error bars indicate 95% conﬁdence intervals of the GMT, *** p < 0.0001. On Day 42, mice were infected
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with  1000 pfu mouse adapted Zaire EBOV strain 1976 Mayinga. Following challen
aplan-Meier survival curve for infected mice. Statistical analysis of Kaplan-Meier 
By Day 60, the number of IFN- secreting cells in spleens from
ice immunized with EBOV/Mak GP with 5 g of Matrix-M was still
2-fold higher than observed in mice immunized with EBOV/Mak
P alone and 3-fold higher than in mice immunized with EBOV/Mak
P with AlPO4 (Fig. 2B). The increased numbers of IFN- secreting
ells in mice immunized with EBOV/Mak GP with 2.5 g Matrix-M
ere also maintained at Day 60 but at a lower level than with 5 g
atrix-M.
We further assessed Matrix-M induced CD4+ and CD8+ T cell
esponses by intracellular staining of cytokines combined with
ell surface markers. Analysis of splenocytes by ﬂowcytometric
taining at Day 28 showed that both CD4+ and CD8+ T cells from
BOV/Mak GP with Matrix-M groups secreted IFN-, TNF and
L-2 (Fig. 2C–E). The frequency of cytokine-secreting CD4+ and
D8+ T cells was much higher in spleens from the EBOV/Mak
P with Matrix-M groups than the responses observed in con-
rol mice (PBS or Matrix-M alone), mice receiving EBOV/Mak GP
lone or EBOV/Mak GP with AlPO4 (Fig. 2C–E). The frequency of
 cells that simultaneously produce two or three cytokines was
lso evaluated at Day 28. Both CD4+ and CD8+ T cells produc-
ng either two or three cytokines were detected at marked levels
nly in spleens from the mice immunized with EBOV/Mak GP with
atrix-M..3. Germinal center and T follicular helper cell responses
The frequency and absolute number of GC B cells in the spleen
ere analysed by ﬂowcytometric staining (Fig. 3A). The analysisice were observed daily for morbidity and mortality for a period of 21 days. (C)
al curve was  done by Log-Rank analysis.
showed that at Day 28, EBOV/Mak GP adjuvanted with 2.5 and 5 g
of Matrix-M induced responses with a GC frequency of 1.99 ± 0.80%
and 2.83 ± 1.63%, respectively, in comparison to placebo, Matrix-
M control, EBOV/Mak GP alone or EBOV/Mak GP with AlPO4
(0.51 ± 0.09, 0.72 ± 0.25, 0.66 ± 0.13 and 0.75 ± 0.51%, respectively)
(Fig. 3B). Accordingly, the absolute GC cell number in the spleen
also increased in the groups receiving Matrix-M (Fig. 3C). By Day
60, the frequency and absolute number returned to background
level (Fig. 3D and E).
Analysis of TFH cells frequencies at Day 28 showed that
EBOV/Mak GP with 2.5 or 5 g of Matrix-M induced higher frequen-
cies of TFH cells than the EBOV/Mak GP alone or with AlPO4 (Fig. 4A
and B). Accordingly, the absolute number of TFH cells was also
enhanced by EBOV/Mak GP with Matrix-M compared to EBOV/Mak
GP alone or with AlPO4 (Fig. 4C). By Day 60, the frequency and abso-
lute number of TFH cells retracted to near background levels (Fig. 4D
and E).
3.4. Persistence of EBOV/Mak GP-speciﬁc plasma cells in bone
marrow
In order to assess the inﬂuence of Matrix-M on the formation of
EBOV/Mak GP-speciﬁc plasma cells, the number of IgG-producing
cells in spleen and bone marrow was analysed in ELISPOT assays at
Day 60 after immunization. The analysis at Day 60 demonstrated
only a few EBOV/Mak GP-speciﬁc IgG-secreting cells (<6/106
splenocytes) in the spleens from mice immunized with Matrix-M
adjuvanted EBOV/Mak GP vaccine (Fig. 5A). No IgG-secreting cells
K.L. Bengtsson et al. / Vaccine 34 (2016) 1927–1935 1931
Fig. 2. Matrix-M enhanced CD4+ T cell and CD8+ T cell responses and multifunctional T cell response to EBOV/Mak GP. Spleen cells were stimulated with EBOV/Mak GP
peptide  pools covering the entire GP sequence. Culture medium or PMA  (50 ng/ml) plus ionomycine (200 ng/ml) were used as negative and positive controls. IFN- positive
spots  from Day 28 (A) and 60 (B) were counted and analyzed with an ELISPOT reader and associated software. Background numbers of the medium controls were subtracted
from  the numbers of peptides-stimulated wells and a mean was  derived from the triplicates. Cells from all ﬁve mice in the same group at Day 28 were pooled and incubated
with  either medium alone, or GP peptide pools, or PMA  plus ionomycin for 6 h at 37 ◦C with the presence of BD Golgi-stop/Golgi-plug. Cells were then harvested and
stained  for cell surface markers and intracellular cytokines. Frequency of cytokines was  analyzed using Flowjo software and Flowjo Boolean function by gating on live
CD3+CD44+CD62L−CD4+ effector memory T cells or live CD3+CD44+CD62L−CD8+ effector memory T cells. The sum for single cytokines, double cytokines or triple cytokines
represent the sum of the frequency of cells expressing any one of the three cytokines (IFN-, TNF and IL-2), any two of the three cytokines or all three cytokines. The
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ndicate group means and error bars represent standard deviation, * p < 0.05, ** p < 0
ere detected in the spleens from mice immunized with EBOV/Mak
P alone and EBOV/Mak GP with AlPO4 (Fig. 5A). In contrast, high
umbers of EBOV/Mak GP-speciﬁc IgG-secreting cells appeared
n bone marrow from mice that received Matrix-M adjuvanted
BOV/Mak GP (Fig. 5B), demonstrating residency of EBOV/Mak GP
peciﬁc plasma cells in the bone marrow.e pie chart (D). The result is representative of two  separate experiments. Black bars
** p < 0.0001.
4. DiscussionFor reasons not fully understood, the EBOV surface glycoprotein
has proven to be inherently poorly immunogenic requiring either
genetic vectors or strong adjuvant to induce substantial and pro-
tective immune responses. Due to these factors we explored the
1932 K.L. Bengtsson et al. / Vaccine 34 (2016) 1927–1935
Fig. 3. Matrix-M enhanced GC cell response. Fresh splenocytes were stained for GC B cells and data was acquired as described in Materials and Methods. Data was  analyzed
with  Flowjo software. Dead cells were excluded from analysis with Invitrogen LIVE/DEADTM ﬁxable yellow dye. (A), GC cells were deﬁned as CD95+GL-7+ on B220+ B cell
gate  and the numbers in the dot-plot of representative mice indicate the mean and standard deviation of GC frequency from all ﬁve mice in the same group at Day 28. GC
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mell  frequencies from individual mice are shown for Days 28 (B) and Day 60 (D). 
ultiplying the frequency of GC cells with the total number of splenocytes in the
 < 0.05, ** p < 0.01.
se of the saponin adjuvant, Matrix-M, for the development of a
rotective, protein-based vaccine against EBOV disease.
In the present study, a recombinant EBOV/Mak full length GP
anoparticle vaccine formulated with Matrix-M, AlPO4 or saline
as evaluated. Immunization of mice with non-adjuvanted or
lPO4 adjuvanted EBOV/Mak GP induced modest antibody and cel-
ular responses. The inability of AlPO4 to enhance the production of
nti-EBOV/Mak GP IgG was unexpected. One possible explanation
s that the structure of the GP nanoparticle is critical for an optimal
ntibody response and absorption of the nanoparticle onto AlPO4
ltered the nanoparticle structure.
When adjuvanted with Matrix-M, puriﬁed EBOV/Mak GP
anoparticles were highly immunogenic and protective in a murine
hallenge model. Immunization of mice with Matrix-M adjuvanted
BOV/Mak GP resulted in a signiﬁcant increase in anti-EBOV/Mak
P IgG and EBOV neutralizing antibody. In addition, Matrix-M adju-
anted EBOV/Mak GP conferred 100% protection from a lethal EBOV
hallenge.Co-administration of the EBOV/Mak GP with Matrix-M induced
he production of a balanced IgG1 and IgG2a subclass response
see Supplemental Data). In the absence of adjuvant or with AlPO4,
inimal IgG2a antibody was detected. Blaney et al. [33], showedsolute GC cell number per spleen from Days 28 (C) and 60 (E) was calculated by
n. Black bars indicate group means and error bars represent standard deviation, *
in a rabies/EBOV chimaera vaccine model in non-human primates
(NHP) that the antibody isotype played a role in virus neutralization
and protection against EBOV challenge. Murine IgG2a antibody is
the equivalent of human IgG1 antibody that binds efﬁciently to IgG-
Fc receptors (FcR) and complement (C1q) [34,35] and may  help
resolving viral infections e.g., through antibody-dependent cell-
mediated cytotoxicity. The beneﬁts of IgG class switch to murine
IgG2a isotype was reported by Wilson and co-workers [36] who
raised a panel of monoclonal antibodies to the EBOV glycoprotein.
All antibodies that were completely protective in vivo were of the
IgG2a subclass.
Matrix-M adjuvant has been evaluated in numerous preclinical
studies [4,6–12] without any reports of cytotoxicity or side effects.
In clinical trials the use of Matrix-M has been reported as well tol-
erated and was demonstrated to have dose sparing properties [5].
However, Matrix-M adjuvanticity has been associated with a potent
induction of leukocyte activation and migration into the draining
lymph nodes [10–12]. Even though there is no evidence of pattern-
recognition receptor stimulation by Matrix-M, there is a strong
activation of T cells [3,5–7,10]. The presence of CD8+ T cells secret-
ing IFN- and TNF- [37], as well as CD4+ T cells secreting IFN-
and IL-2 [38,39] or TNF- [25], have been reported to correlate with
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Fig. 4. Matrix-M enhanced the frequency and absolute number of TFH cells in the spleen. TFH cells, deﬁned as CXCR5+PD-1+ T cells within B220−CD49b− CD3+CD4+ T cell gate,
were  identiﬁed in spleens at Days 28 and 60. Representative dot-plot of TFH cell analysis from each group is shown (A). The number in the dot-plot is the average frequency
and  standard deviation from Day 28. The frequency of TFH cells within the CD4+ T cell population from Days 28 (B) and 60 (D) is shown. The absolute TFH cell number per
spleen  from Days 28 (C) and 60 (E) was calculated by multiplying the frequency of TFH cells with the total number of splenocytes in the spleen. Black bars indicate group
means and error bars represent standard deviation, * p < 0.05.
Fig. 5. Matrix-M induced persistence of EBOV/Mak GP speciﬁc plasma cells in bone marrow. Spleen and bone marrow cells were incubated overnight in EBOV/Mak GP coated
E ith goa
a ) per m
D up me
s
a
f
i
pLISPOT plates. The EBOV/Mak GP-speciﬁc IgG spots were detected by incubating w
nd  analyzed using an ELISPOT reader. The number of antibody secreting cells (ASC
ay  60 EBOV/Mak GP-IgG ASC number in the bone marrow. Black bars indicate gro
urvival. T cells that simultaneously produce two or more cytokines
re deﬁned as multifunctional T cells, and the number of multi-
unctional T cells is associated with a better effector activity and
mmunologic memory [40–42]. The use of the Matrix-M adjuvant
rovided a dose dependent increase in the frequency of CD4+ andt-anti-mouse IgG-HRP followed by spot development. Spot numbers were counted
illion cells is shown. (A) Day 60 EBOV/Mak GP-IgG ASC number in the spleen; (B)
ans and error bars represent standard deviation, * p < 0.05.
CD8+ cytokine secreting T cells as well as the number of multifunc-
tional T cells producing more than one cytokine. The observation
that protection from a lethal EBOV challenge was observed only in
the Matrix-M adjuvanted EBOV/Mak GP group was associated with
the enhanced production of multifunctional T cells.
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The use of Matrix-M increased the frequency of GC B cells in
he spleen and EBOV/Mak GP-speciﬁc plasma cells in the bone
arrow. GCs are the micro-anatomic locations for B cell differ-
ntiation, somatic hypermutation, antibody class-switching and
ormation of memory B cells [23,24,43]. Co-administration of the
BOV/Mak GP with Matrix-M also resulted in an increase of the
umbers of TFH cells which facilitate GC B cell differentiation and
evelopment [23,24,43–46]. The increased frequency of GC and TFH
ells induced by Matrix-M adjuvantation was associated with the
nhanced magnitude of the antibody response and the induction
f a greater numbers of GP-speciﬁc plasma cells in the bone mar-
ow. This would suggest that the Matrix-M adjuvanted EBOV/Mak
P vaccine has the potential to induce a durable antibody response.
ur novel observation of Matrix-M driven stimulation of GC forma-
ion and increased frequencies of TFH cells, not reported before, is
ell in line with the typical humoral responses evoked by Matrix-M
djuvanted antigens [10,13].
In summary, our data indicates that co-administration of the
atrix-M adjuvant with puriﬁed EBOV/Mak GP nanoparticles
rovides robust stimulation of the anti-EBOV/Mak GP immune
esponse resulting in 100% protective efﬁcacy in the mouse model.
e observed a more rapid onset of anti-EBOV/Mak GP IgG and EBOV
eutralization antibodies, increased concentration of IgG2a, as well
s increased frequency of multifunctional CD4+ and CD8+ T cells,
FH cells, germinal center B cells and persistence of EBOV/Mak GP-
peciﬁc plasma B cells in the bone marrow. These data, along with
he reported safety proﬁle of Matrix-M in clinical trials, have pro-
ressed the investigation of this vaccine into NHP studies and a
hase I clinical trial.
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